| Date Filed | Type | Description |
| 02/14/2022 |
SC 13G/A
| Alyeska Investment Group, L.P. reports a 0% stake in Oxford Immunotec Global PLC |
| 02/14/2022 |
SC 13G/A
| Polar Capital Holdings Plc reports a 0% stake in Oxford Immunotec Global PLC |
| 05/07/2021 |
SC 13G
| Grandeur Peak Global Advisors, LLC reports a 2.2% stake in Oxford Immunotec Global PLC |
| 03/18/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 03/12/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/12/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/08/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/08/2021 |
8-K
| Quarterly results |
| 03/08/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/02/2021 |
8-K/A
| Quarterly results |
| 02/26/2021 |
8-K
| Quarterly results |
| 02/17/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/17/2021 |
SC 13G/A
| Endurant Capital Management LP reports a 0% stake in Oxford Immunotec Global PLC |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2021 |
SC 13G
| Endurant Capital Management LP reports a 8.6% stake in Oxford Immunotec Global PLC |
| 02/11/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2021 |
SC 13G
| Grandeur Peak Global Advisors, LLC reports a 2.2% stake in Oxford Immunotec Global PLC |
| 02/10/2021 |
SC 13G/A
| First Light Asset Management, LLC reports a 0.4% stake in Oxford Immunotec Global PLC |
| 02/08/2021 |
GN
| Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea |
| 02/04/2021 |
GN
| Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses |
| 02/03/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/29/2021 |
SC 13D
| Magnetar Financial LLC reports a 7.8% stake in OXFORD IMMUNOTEC GLOBAL PLC |
| 01/29/2021 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 01/21/2021 |
GN
| MERGER INVESTIGATION: Halper Sadeh LLP Investigates CMD, COHR, PS, OXFD; Shareholders Are Encouraged to Contact the Firm |
| 01/20/2021 |
GN
| SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Oxford Immunotec Global PLC Buyout |
| 01/19/2021 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 01/13/2021 |
GN
| Oxford Immunotec's T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva's VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study |
| 01/08/2021 |
SC 13G/A
| First Light Asset Management, LLC reports a 19.4% stake in Oxford Immunotec Global PLC |
| 01/07/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/07/2021 |
8-K
| Quarterly results |
|